EUVIMEDEUVIMED entdecken
Vergleichsstudie

Bladder neck involvement in non‐muscle‐invasive bladder cancer: risk implications and outcomes of BCG vs gemcitabine/docetaxel

Ahmed Eraky iD, Reuben Ben-David iD, Brenda Hug iD, Kaushik P Kolanukuduru iD, Neeraja Tillu iD, Peter Wiklund iD, Reza Mehrazin, John P Sfakianos

BJU International · 2025

DOI: 10.1111/bju.16827 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift BJU International, 2025. Verfasst von Ahmed Eraky und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Icahn School of Medicine at Mount Sinai Hospital, New York, NY, USA. Hauptthemen laut MEDLINE: Urinary Bladder Neoplasms, BCG Vaccine, Docetaxel, Deoxycytidine. Die Arbeit nennt 29 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

To evaluate the impact of bladder neck involvement (BNI) on oncological outcomes in non‐muscle‐invasive bladder cancer (NMIBC) and compare outcomes between Bacillus Calmette‐Guérin (BCG) and gemcitabine/docetaxel (Gem/Doce) intravesical therapies in this population. Patients and Methods We analysed consecutive patients with NMIBC who underwent transurethral resection of bladder tumour (TURBT) and received BCG or Gem/Doce from 2013 to 2023. BNI was defined as tumour presence at the bladder neck during TURBT. Recurrence‐free survival (RFS) and progression‐free survival (PFS) were assessed using Kaplan–Meier and Cox regression analyses.

Results

Among 474 patients, 58 (12%) had BNI. The median (interquartile range) follow‐up time was 34 (12–58) months. The 2‐year RFS was lower in the BNI group for any‐grade (41% vs 57%, log‐rank p = 0.003) and high‐grade recurrence (56% vs 68%, log‐rank p = 0.03). BNI independently predicted worse any‐grade RFS (hazard ratio [HR] 1.59, p = 0.02), high‐grade RFS (HR 1.68, p = 0.03), and PFS (HR 2.18, p = 0.03). While BCG and Gem/Doce had comparable 2‐year high‐grade RFS (59% vs 53%, log‐rank p = 0.31) and PFS (88% vs 68%, log‐rank p = 0.07), the multivariable analysis revealed significantly increased risk of any‐grade recurrence (HR 1.75, p < 0.001) and progression (HR 2.72, p = 0.002). Maintenance therapy improved high‐grade RFS (HR 0.43, p < 0.001) and PFS (HR 0.44, p = 0.003). Limitations include retrospective design and single‐institution data.

Conclusion

Bladder neck involvement is an independent predictor of worse outcomes in NMIBC. While unadjusted outcomes were similar, multivariable analysis showed higher recurrence and progression risk with Gem/Doce. Recognising BNI as a high‐risk factor may refine risk stratification and treatment decisions. Further studies are needed to validate these findings.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Urinary Bladder NeoplasmsBCG VaccineDocetaxelDeoxycytidineAntineoplastic Combined Chemotherapy ProtocolsHumansMaleFemaleGemcitabineAgedMiddle AgedRetrospective StudiesNeoplasm InvasivenessNeoplasm Recurrence, LocalTreatment OutcomeAdministration, IntravesicalAged, 80 and overAdjuvants, ImmunologicNon-Muscle Invasive Bladder Neoplasms

Stichwörter der Autor:innen

Bacillus Calmette‐Guérin (BCG)bladder neck involvementgemcitabine/docetaxelintravesical therapynon‐muscle‐invasive bladder cancer

Substanzen

GemcitabineBCG VaccineDocetaxelDeoxycytidineAdjuvants, Immunologic

Autor:innen und Institutionen

  • Department of Urology, Icahn School of Medicine at Mount Sinai Hospital, New York, NY, USA.

ORCID-Profile: Ahmed Eraky, Reuben Ben-David, Brenda Hug, Kaushik P Kolanukuduru, Neeraja Tillu, Peter Wiklund

Zitieren

APA

Eraky, A., Ben-David, R., Hug, B., Kolanukuduru, K. P., Tillu, N., Wiklund, P., Mehrazin, R., & Sfakianos, J. P. (2025). Bladder neck involvement in non‐muscle‐invasive bladder cancer: risk implications and outcomes of BCG vs gemcitabine/docetaxel. BJU International. https://doi.org/10.1111/bju.16827

Vancouver

Eraky A, Ben-David R, Hug B, Kolanukuduru KP, Tillu N, Wiklund P, et al. Bladder neck involvement in non‐muscle‐invasive bladder cancer: risk implications and outcomes of BCG vs gemcitabine/docetaxel. BJU International. 2025. doi:10.1111/bju.16827

BibTeX
@article{Eraky2025,
  author = {Eraky, Ahmed and Ben-David, Reuben and Hug, Brenda and Kolanukuduru, Kaushik P and Tillu, Neeraja and Wiklund, Peter and Mehrazin, Reza and Sfakianos, John P},
  title = {Bladder neck involvement in non‐muscle‐invasive bladder cancer: risk implications and outcomes of BCG vs gemcitabine/docetaxel},
  journal = {BJU International},
  year = {2025},
  doi = {10.1111/bju.16827}
}
Kostenlos starten →